Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
Open Access
- 1 January 2019
- journal article
- review article
- Published by MDPI AG in Antibodies
- Vol. 8 (1) , 3
Abstract
The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution. This review provides an updated summary of factors known to affect the disposition of mAbs/ADCs in development and in clinical use, as well as how these factors should be considered in the selection and design of preclinical studies of ADC agents in development.Keywords
This publication has 277 references indexed in Scilit:
- Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancerCancer Chemotherapy and Pharmacology, 2013
- Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged MiceCancer Research, 2012
- Protective and pathogenic functions of macrophage subsetsNature Reviews Immunology, 2011
- Macrophage-mediated inflammation in metabolic diseaseNature Reviews Immunology, 2011
- B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodiesNature Medicine, 2011
- Enhanced antibody half-life improves in vivo activityNature Biotechnology, 2010
- Exploring the full spectrum of macrophage activationNature Reviews Immunology, 2008
- Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studiesThe Lancet, 2008
- The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trialsBritish Journal of Cancer, 2007
- Comparison of treatment effects between animal experiments and clinical trials: systematic reviewBMJ, 2006